CAMBRIDGE TECHNOLOGIES LLC

WORTHINGTON, MN · CIK 0001726306 · Biotech

cambridgetechnologies.com →
Grants
$742K
2 awards
Sector median: 1
Raised
$3.5M
1 Form D · Jan 2018
105 months since last filing
Contracts
—
No federal contracts on record
Patents
5
3 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$3,500,000
Federal grantDepartment of Agriculture · Universal Swine Influenza Vaccine$100,000
Federal grantDepartment of Agriculture · Universal Swine Influenza Vaccine$641,800
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1916Origin Protocol, Inc.—$38M
1917NGM Bio Holdings, Inc.—$73M
1918CELESTIAL THERAPEUTICS INC—$125K
1919CAMBRIDGE TECHNOLOGIES LLC—$3.5M
1920ONCOTHERAPY SOLUTIONS, LLC——
1921WILD MICROBES CO——
1922Onramp Invest, Inc.—$5.0M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Marc FreeseDirector
  • Wayne FreeseDirector · Executive Officer
  • Reed LeitingDirector
  • James RasmussenDirector
  • Randy SimonsonDirector · Executive Officer
  • Carl StonerDirector
  • Donna TimsDirector · Executive Officer

Patents

USPTO · 3 granted of 5

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.